Meeting
2022 ASCO Annual Meeting
Observer performance study to examine the feasibility of the AI-powered PD-L1 analyzer to assist pathologists’ assessment of PD-L1 expression using tumor proportion score in non–small cell lung cancer.
Authors
Seokhwi Kim
Department of Pathology, Ajou University School of Medicine, Suwon, South Korea
Seokhwi Kim , Hyojin Kim , Wonkyung Jung , Soo Ick Cho , Joel Bentz , Warren Clingan , Kevin Golden , Ramir Arcega , Hyunsik Bae , Dawn L. Butler , Sangjoon Choi , Maryam Farinola , Daniel Harrison , Soohyun Hwang , Minsun Jung , Nilesh Kashikar , Hyunsung Kim , Julia Manny , Carmen Winters , Jonathan H. Hughes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8529)
DOI
10.1200/JCO.2022.40.16_suppl.8529
Abstract #
8529
Poster Bd #
156
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Heterogeneity of PD-L1 expression among resected EGFR-mutated NSCLC and prognostic implications.
First Author: Stephanie Pei Li Saw
Poster
2023 ASCO Annual Meeting
A comprehensive pan-cancer analysis of PD-L1 expression using clone E1L3N in Chinese patients with cancer.
First Author: Huangbin Lu
Poster
2021 ASCO Annual Meeting
Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) in advanced non-small cell lung cancer (NSCLC).
First Author: Hyojin Kim
Poster
2023 ASCO Annual Meeting
The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer.
First Author: Petros Christopoulos